Динамика простатспецифического антигена в ближайший период после сочетанной лучевой терапии рака предстательной железы

Abstract

50 patients with prostate cancer (PC) had undergone external beam radiation therapy with 60Co with a dose 30- 44 Gy and high dose rate brachytherapy (two implantations on 8.5 Gy). 21 patients without orchiectomy (first group). To 29 patients executed orchiectomy before the beam treatment (the second group). All patients received adjuvant hormonal therapy. Prostat-specific antigen decreased after 6 months of beam therapy: in the first group to 2.5 ng/ml (initial level — 16.0 ng/ml). In the second group — 0.3 ng/ml; 19.5 ng/ml accordingly. Acute genitourinary toxicity in the first group Grade (G) 1 — 33.3 %, G 2 — 28.6 %, in the second group — 31.0 and 24.2 % accordingly, in 1 case (3.4%) — G 4. Acute intestine toxicity in the first group were G 1 — 57.1%, G 2 — 14.3%, in the second group — 27.6%; 10.3% accordingly.